Hidradenitis Suppurativa trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Hidradenitis Suppurativa. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month7 studies across 4 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| MLTX | MoonLake Immunotherapeutics AG | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)NCT06768671Pharmacokinetics (PK) of sonelokimab in adolescents | Phase 3 | Active, not recruiting | 2026-09-28 | in 39 d | 2026-05-06 |
October 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| INCY | Incyte Corporation | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)NCT06958211Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline | Phase 3 | Active, not recruiting | 2026-10-09 | in 50 d | 2026-07-08 |
| INCY | Incyte Corporation | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)NCT06959225Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline | Phase 3 | Active, not recruiting | 2026-10-09 | in 50 d | 2026-07-28 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ZURA | Zura Bio Inc | Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610[Period 1] Percent change from baseline in abscess and inflammatory nodule (AN) count at 16 weeks | Phase 2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2026-06-30 |
December 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| INCY | Incyte Corporation | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaNCT07049575Number of participants with Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | 2026-12-09 | in 111 d | 2026-08-06 |
| INCY | Incyte Corporation | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaNCT06212999Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) | Phase 3 | Active, not recruiting | 2026-12-26 | in 128 d | 2026-03-23 |
| ABBV | AbbVie | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaNCT06468228Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 75 | Phase 3 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-08-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Hidradenitis Suppurativa
most recently updated first52 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALM.MC | Almirall, S.A. | $2.2B | A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis SuppurativaNCT07547813Proportion of Participants Achieving 55 Percent (%) Reduction from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4-55) | Phase 2 | Recruiting | Drug: LAD328 · Other: Placebo | Hidradenitis Suppurativa | 50 | 2026-05-13 | Feb 2027 | ≤ 192 d | 2026-08-17 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyNCT05889182Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 50 | Phase 3 | Active, not recruiting | Drug: Upadacitinib, Placebo | Hidradenitis Suppurativa | 1,328 | 2023-06-21 | Mar 2028 | ≤ 589 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaNCT06468228Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 75 | Phase 3 | Active, not recruiting | Drug: Lutikizumab, Placebo | Hidradenitis Suppurativa | 1,400 | 2024-06-27 | Dec 2026 | ≤ 133 d | 2026-08-14 |
| SYRE | Spyre Therapeutics, Inc. | $9.5B | A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)NCT07766005Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) | Phase 2 | Not yet recruiting | Drug: SPY072, Placebo, bimekizumab | Hidradenitis Suppurativa (HS) | 150 | Sep 2026 | Oct 2027 | ≤ 437 d | 2026-08-14 |
| MLTX | MoonLake Immunotherapeutics AG | $1.4B | A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06411899Hidradenitis Suppurativa Clinical Response 75 | Phase 3 | Completed | Drug: Sonelokimab, Placebo | Hidradenitis Suppurativa | 422 | 2024-05-15 | 2025-09-02actual | — | 2026-08-12 |
| INCY | Incyte Corporation | $24.7B | Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibNCT06855498Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) | Phase 3 | Recruiting | Drug: povorcitinib | Hidradenitis Suppurativa (HS) | 600 | 2025-02-28 | 2028-02-28 | in 557 d | 2026-08-06 |
| INCY | Incyte Corporation | $24.7B | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaNCT07049575Number of participants with Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: Ruxolitinib Cream | Hidradenitis Suppurativa | 24 | 2025-11-03 | 2026-12-09 | in 111 d | 2026-08-06 |
| INCY | Incyte Corporation | $24.7B | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaNCT07213973Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) | Phase 2 | Recruiting | Drug: Povorcitinib | Hidradenitis Suppurativa (HS) | 40 | 2026-02-02 | 2028-03-25 | in 583 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06046729Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) | Phase 2 | Active, not recruiting | Drug: Eltrekibart, Placebo | Hidradenitis Suppurativa | 352 | 2023-10-23 | 2025-09-30actual | — | 2026-08-04 |
| INCY | Incyte Corporation | $24.7B | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)NCT06959225Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline | Phase 3 | Active, not recruiting | Drug: Ruxolitinib Cream, Vehicle Cream | Hidradenitis Suppurativa | 580 | 2025-06-23 | 2026-10-09 | in 50 d | 2026-07-28 |
| PFE | Pfizer | $155.3B | A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.NCT07228390Difference in proportion of responders based on Hidradenitis Suppurativa Clinical Response achieving at least 50% reduction from baseline (Hidradenitis Suppurativa Clinical Response HiSCR50) in patients with HS treated with ritlecitinib versus placebo. | Phase 2 | Recruiting | Drug: Ritlecitinib, Placebo | Hidradenitis Suppurativa | 240 | 2025-11-13 | 2027-03-05 | in 197 d | 2026-07-09 |
| INCY | Incyte Corporation | $24.7B | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)NCT06958211Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline | Phase 3 | Active, not recruiting | Drug: Ruxolitinib Cream, Vehicle Cream | Hidradenitis Suppurativa | 573 | 2025-06-12 | 2026-10-09 | in 50 d | 2026-07-08 |
| SNY | Sanofi | — | A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT07225569Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) | Phase 2 | Recruiting | Drug: SAR445399, Placebo | Hidradenitis Suppurativa | 144 | 2025-12-29 | 2027-09-22 | in 398 d | 2026-07-01 |
| ZURA | Zura Bio Inc | $553M | Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610[Period 1] Percent change from baseline in abscess and inflammatory nodule (AN) count at 16 weeks | Phase 2 | Active, not recruiting | Biological: Tibulizumab Dose A, Tibulizumab Dose B · Other: Placebo | Hidradenitis Suppurativa (HS) | 225 | 2025-05-16 | Nov 2026 | ≤ 102 d | 2026-06-30 |
| INSM | Insmed Incorporated | $28.1B | A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)NCT06685835Percent Change From Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Week 16 | Phase 2 | Terminatedsponsor's stated reason: Lack of Efficacy | Drug: Brensocatib, Placebo | Hidradenitis Suppurativa | 214 | 2024-12-16 | 2026-02-12actual | — | 2026-06-29 |
| SNY | Sanofi | — | Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaNCT07170917Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) | Phase 2 | Recruiting | Drug: Brivekimig, Placebo | Hidradenitis Suppurativa | 208 | 2025-11-06 | 2027-08-01 | in 346 d | 2026-06-12 |
| MLTX | MoonLake Immunotherapeutics AG | $1.4B | Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06411379Hidradenitis Suppurativa Clinical Response 75 | Phase 3 | Completed | Drug: Sonelokimab, Placebo | Hidradenitis Suppurativa | 418 | 2024-05-14 | 2025-08-14actual | — | 2026-06-08 |
| MLTX | MoonLake Immunotherapeutics AG | $1.4B | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaNCT07007637Long-term safety and tolerability of sonelokimab: Adverse events (AEs) following treatment with sonelokimab | Phase 3 | Enrolling by invitation | Drug: Sonelokimab | Hidradenitis Suppurativa | 835 | 2025-06-27 | 2028-06-13 | in 663 d | 2026-06-08 |
| SNY | Sanofi | — | SAR447971 First-in-human StudyNCT07629336SAD20411: Incidence of treatment emergent adverse events (TEAEs) | Phase 1 | Recruiting | Drug: SAR447971, Placebo | Hidradenitis, Healthy Volunteers | 114 | 2026-05-26 | 2028-02-16 | in 545 d | 2026-06-05 |
| ALM.MC | Almirall, S.A. | $2.2B | A Study of LAD191 in Adults With Hidradenitis SuppurativaNCT07151937Proportion of Participants Achieving 50 Percent (%) Reduction from Baseline in Hidradenitis Suppurativa Clinical Response (HiSCR-50) | Phase 2 | Recruiting | Drug: LAD191, Adalimumab · Other: Placebo | Hidradenitis Suppurativa | 200 | 2025-11-05 | 2027-05-25 | in 278 d | 2026-05-11 |
| MLTX | MoonLake Immunotherapeutics AG | $1.4B | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)NCT06768671Pharmacokinetics (PK) of sonelokimab in adolescents | Phase 3 | Active, not recruiting | Drug: Sonelokimab | Hidradenitis Suppurativa | 35 | 2024-12-30 | 2026-09-28 | in 39 d | 2026-05-06 |
| AVTX | Avalo Therapeutics, Inc. | $1.1B | A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis SuppurativaNCT06603077Proportion of patients achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) | Phase 2 | Completed | Drug: AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo | Hidradenitis Suppurativa | 253 | 2024-09-16 | 2026-02-23actual | — | 2026-04-21 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaNCT06212999Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) | Phase 3 | Active, not recruiting | Drug: Povorcitinib | Hidradenitis Suppurativa (HS) | 617 | 2024-01-30 | 2026-12-26 | in 128 d | 2026-03-23 |
| ABBV | AbbVie | $457.5B | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic TherapyNCT05139602Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) | Phase 2 | Active, not recruiting | Biological: Lutikizumab · Drug: Placebo | Hidradenitis Suppurativa | 210 | 2021-12-28 | Dec 2027 | ≤ 498 d | 2026-02-13 |
| ABBV | AbbVie | $457.5B | A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis SuppurativaNCT07136467observationalAlopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only | — | Recruiting | — | Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa | 2,795 | 2025-09-02 | Aug 2027 | ≤ 376 d | 2026-02-13 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaNCT05620823Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR) | Phase 3 | Completed | Drug: Povorcitinib, Placebo | Hidradenitis Suppurativa (HS) | 608 | 2022-12-19 | 2025-02-03actual | — | 2026-02-10 |
| SNY | Sanofi | — | Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06118099The clinical response as measured by the percentage of participants achieving HiSCR50 at Week 16 | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision; the decision is not related to any safety concern | Drug: Amlitelimab, Placebo | Hidradenitis | 90 | 2023-11-01 | 2025-02-06actual | — | 2026-02-04 |
| SNY | Sanofi | — | A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis SuppurativaNCT05849922results2026-01-29Period A (DB Period): Percentage of Biologic and Small Molecule Immunosuppressive-Naïve Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 | Phase 2 | Completed | Drug: SAR442970, Placebo | Hidradenitis Suppurativa | 86 | 2023-06-06 | 2024-08-22actual | — | 2026-01-29 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)NCT05620836Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR) | Phase 3 | Completed | Drug: Povorcitinib, Placebo | Hidradenitis Suppurativa (HS) | 619 | 2023-02-22 | 2025-01-07actual | — | 2026-01-09 |
| ACRS | Aclaris Therapeutics, Inc. | $928M | ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)NCT05216224results2026-01-07Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12 | Phase 2 | Completed | Drug: ATI-450, Placebo oral tablet | Hidradenitis Suppurativa | 95 | 2021-12-29 | 2022-12-23actual | — | 2026-01-07 |
| SNY | Sanofi | — | A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06028230Percent change from baseline in total abscess and inflammatory nodule (AN) count | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision. Not related to safety concern. | Drug: SAR444656 (KT-474), Placebo | Hidradenitis Suppurativa | 70 | 2023-09-29 | 2025-10-09actual | — | 2025-12-11 |
| VNDA | Vanda Pharmaceuticals | $329M | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis SuppurativaNCT04856930results2025-09-22Change From Baseline in AN Count at Week 16: Placebo-Controlled Period | Phase 2 | Completed | Biological: Imsidolimab, Placebo | Hidradenitis Suppurativa | 149 | 2021-07-07 | 2022-07-15actual | — | 2025-09-22 |
| INCY | Incyte Corporation | $24.7B | A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaNCT03607487results2020-09-21Number of Treatment-emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: INCB054707, Placebo | Hidradenitis Suppurativa | 35 | 2018-10-15 | 2019-08-13actual | — | 2025-08-21 |
| INCY | Incyte Corporation | $24.7B | To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaNCT04476043results2023-01-26Mean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16 | Phase 2 | Completed | Drug: INCB054707, Placebo | Hidradenitis Suppurativa, Acne Inversa | 209 | 2020-08-25 | 2021-12-15actual | — | 2025-08-12 |
| AMGN | Amgen | $229.9B | Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)NCT03852472results2024-03-15Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12. | Phase 2 | Completed | Drug: Avacopan · Other: Placebo | Hidradenitis Suppurativa, Acne Inversa | 435 | 2018-12-21 | 2021-01-14actual | — | 2025-03-17 |
| ABBV | AbbVie | $457.5B | A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of LutikizumabNCT06524635Number of Participants With Adverse Events (AEs) | Phase 2 | Recruiting | Drug: Lutikizumab | Hidradenitis Suppurativa, Atopic Dermatitis | 60 | 2024-08-14 | Feb 2027 | ≤ 192 d | 2025-01-24 |
| INCY | Incyte Corporation | $24.7B | Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis SuppurativaNCT05635838results2024-11-01Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16 | Phase 2 | Completed | Drug: Ruxolitinib cream, Vehicle cream | Hidradenitis Suppurativa | 69 | 2022-12-07 | 2023-10-19actual | — | 2024-11-01 |
| MLTX | MoonLake Immunotherapeutics AG | $1.4B | Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaNCT05322473Hidradenitis Suppurativa Clinical Response 75 | Phase 2 | Completed | Drug: Sonelokimab (M1095), Adalimumab · Other: Placebo | Hidradenitis Suppurativa | 234 | 2022-04-25 | 2023-05-09actual | — | 2024-05-03 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3041658 in Adults With Hidradenitis SuppurativaNCT04493502results2023-04-28Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 | Phase 2 | Completed | Drug: Placebo, LY3041658 | Hidradenitis Suppurativa | 72 | 2020-08-26 | 2022-03-15actual | — | 2023-04-28 |
| ABBV | AbbVie | $457.5B | A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease SymptomsNCT04430855results2023-02-06Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | Phase 2 | Completed | Drug: Upadacitinib, Placebo | Hidradenitis Suppurativa (HS) | 68 | 2020-07-14 | 2021-04-22actual | — | 2023-02-06 |
| ABBV | AbbVie | $457.5B | Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis SuppurativaNCT03894956observationalPercentage of participants who reported any serious infections during the study | — | Completed | — | Hidradenitis Suppurativa (HS) | 46 | 2019-05-02 | 2021-11-10actual | — | 2022-11-03 |
| KYMR | Kymera Therapeutics, Inc. | $10.1B | A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)NCT04772885Incidence and severity of treatment emergent Adverse Events | Phase 1 | Completed | Drug: KT-474/Placebo, KT-474 | Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa | 154 | 2021-02-23 | 2022-10-20actual | — | 2022-10-24 |
| INCY | Incyte Corporation | $24.7B | A Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaNCT03569371results2020-05-20Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: INCB054707 | Hidradenitis Suppurativa | 10 | 2018-07-17 | 2019-04-22actual | — | 2022-09-26 |
| ABBV | AbbVie | $457.5B | A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT03926169results2022-08-11Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 | Phase 2 | Completed | Drug: Risankizumab, Placebo for risankizumab | Hidradenitis Suppurativa | 243 | 2019-06-03 | 2021-02-02actual | — | 2022-08-11 |
| KYMR | Kymera Therapeutics, Inc. | $10.1B | Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic DermatitisNCT04440410observationalBiomarker Identification | — | Completed | — | Hidradenitis Suppurativa, Dermatitis, Atopic | 40 | 2020-05-28 | 2021-03-24actual | — | 2021-04-13 |
| ABBV | AbbVie | $457.5B | Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa SubjectsNCT03001115observationalAssessing adverse events | — | Completed | — | Hidradenitis Suppurativa (HS) | 17 | 2017-03-10 | 2019-07-31actual | — | 2020-06-12 |
| ABBV | AbbVie | $457.5B | Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-SurgicallyNCT02808975results2020-05-14Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | Phase 4 | Completed | Drug: Placebo, Adalimumab | Hidradenitis Suppurativa (HS) | 206 | 2016-07-18 | 2019-05-16actual | — | 2020-05-14 |
| ABBV | AbbVie | $457.5B | Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis SuppurativaNCT02904902results2019-02-27Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 | Phase 3 | Completed | Drug: adalimumab | Hidradenitis Suppurativa | 15 | 2016-09-06 | 2017-09-01actual | — | 2020-05-12 |
| ABBV | AbbVie | $457.5B | Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of IllnessNCT02896920observationalProportion of participants achieving clinical response using the Hidradenitis Suppurativa Clinical Response measure (HiSCR) at week 24 | — | Completed | — | Hidradenitis Suppurativa (HS) | 165 | 2016-09-20 | 2019-04-29actual | — | 2020-05-01 |
| ABBV | AbbVie | $457.5B | Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life SettingNCT02786576observationalProportion of participants with moderate to severe Hidradenitis Suppurativa (HS) who achieve a clinical response | — | Completed | — | Hidradenitis Suppurativa | 236 | 2016-07-05 | 2019-01-07actual | — | 2020-01-09 |
| ABBV | AbbVie | $457.5B | Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) PatientsNCT02739828results2019-08-09observationalChange From Baseline in DLQI at Week 12 | — | Completed | Biological: Adalimumab | Hidradenitis Suppurativa | 24 | 2016-04-07 | 2018-03-28actual | — | 2019-08-09 |
| AZN | AstraZeneca | — | Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis SuppurativaNCT01838499results2016-09-011) Percentage of Subjects Achieving a Clinically Relevant Response in Physician Global Assessment (PGA), With Score 0,1 or 2 From Baseline to 12 Weeks | Phase 2 | Terminatedsponsor's stated reason: At the planned IA for decision making, no evidence was demonstrated of MEDI8968 activity in reducing (HS) severity or pain over that seen with placebo. | Biological: MEDI8968, Saline | Hidradenitis Suppurativa | 224 | May 2013 | Oct 2014actual | — | 2016-09-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Hidradenitis Suppurativa is matched — 3 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Hidradenitis Suppurativa
- Hidradenitis Suppurativa (HS)
- Hidradenitis
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Hidradenitis Suppurativa” (a text search, wider than this page)